Predictmedix AI positions Smart Health Stations as alternative to animal testing in clinical trials
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) has highlighted the potential of its Smart Health AI Stations amid the Food and Drug Administration (FDA)'s move to phase out mandatory animal testing in drug development. The company sees the regulatory shift as an opportunity to position its technology as a scalable and human-focused alternative for early-stage clinical evaluations.
Predictmedix AI hits scan milestone with Smart Health Stations
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) announced that it has surpassed more than 500,000 scans through its Smart Health AI Stations, reflecting the growing use of its AI-powered screening tools in healthcare, corporate, and public settings. The technology is designed to identify signs of infectious diseases, mental health conditions, and impairment through non-invasive, automated scans.
Predictmedix AI finalizes private placement, advances Smart Health AI Stations
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) announced that it has completed the third and final tranche of its non-brokered private placement, raising C$100,000 to support its market expansion efforts. The company issued 5 million units at $0.02 per unit, with each unit consisting of one common share and a warrant exercisable at $0.05 per share for 24 months.
Predictmedix AI expands in US with AI-powered health screening stations
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) is launching its enhanced Smart Health AI Stations across the United States. The launch, in partnership with Manchester Marketing Group, will introduce AI-powered assessments capable of real-time vital signs screening and substance impairment detection.
Predictmedix AI banks $320,000 as it closes first-tranche of funding
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) announced it has successfully closed the first tranche of its non-brokered private placement, bringing in $320,000 of gross proceeds. It has issued 16 million units at $0.02 per unit, each comprising one common share and one warrant (exercisable at $0.05 for a period of 24 months).
Predictmedix AI shifts focus to AI-powered workplace and public sector health screening
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) has revealed plans to shift its focus toward workplace safety, workforce readiness, and public sector health screening. The company said it is steering away from traditional healthcare applications to focus on real-time health monitoring and screening solutions designed to enhance operational efficiency and reduce risks in industries where safety and compliance are critical.
Predictmedix AI launches C$1M private placement to expand US presence
Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF), a provider of AI-powered health screening technology, announced a proposed non-brokered private placement to raise up to C$1 million. The net proceeds from the offering will be used for general working capital and to expand market opportunities in the United States for its AI-driven health management solutions across enterprise and government sectors, the company said.
